Matthew W. DeAngelis

Biotech Clinical Operations; father, outdoorsman, musician, volunteer, foodie, Rutgers graduate, resident of Monmouth County.

[Saman Maleki, PhD 🇨🇦 🇮🇷 @SMImmunology]

Shame on Russia and its mad leader Putin.

[Matthew W. DeAngelis @matthew2d]

Attending the @MyastheniaOrg virtual 2022 National Patient Conference.

[Myasthenia Gravis Foundation of America @MyastheniaOrg]

Do you live with #myastheniagravis? Don't miss #MGFA's virtual 2022 National Patient Conference on Thursday, Feb. 10 and Friday, Feb. 11. Featuring emerging research, patient stories, updates on MG treatments and more! Learn more and register here: https://t.co/D3Jgyojc0F

[Matthew W. DeAngelis @matthew2d]

@nabsicle Congratulations!

[Matthew W. DeAngelis @matthew2d]

I'm happy to announce that my career journey continues today with @CabalettaBio, as Associate Director, Clinical Operations, to help drive the clinical development of T cell therapies for autoimmune disease.
#celltherapy #autoimmunedisease #rarediseases #myastheniagravis #CAART

[Matthew W. DeAngelis @matthew2d]

@biopharmasleuth absolutely! I believe it is called confectionary replantation.

[Matthew W. DeAngelis @matthew2d]

(2/2) These data supported an sNDA and label update last year. I'm proud to have contributed to the effort give clinicians robust data supporting the use of Sugammadex in children age 2+. My former colleagues at @Merck continue to study Sugammadex in infants and neonates.

[Matthew W. DeAngelis @matthew2d]

https://t.co/y7AS5lpF6O Happy to share publication of our neurology work from my time at @Merck. We showed that Sugammadex can be safely used in children age 2-17 to rapidly restore neuromuscular function after admin of roc or vec, including reversal from "deep block". (1/2)

[Matthew W. DeAngelis @matthew2d]

@KKajderowicz It’s common to need money to run clinical trials!

[Matthew W. DeAngelis @matthew2d]

( 3 / 3) Thank you @7and8biopharma , and I wish you the best in your continued work to develop the TLR 7/8 portfolio and help address the high unmet needs in the treatment of cancer!

[Matthew W. DeAngelis @matthew2d]

(1/3) Yesterday marked the end of an exciting and successful 1.5 years with @7and8biopharma. I’d like to express my gratitude for the opportunity to help launch the Phase II program for #BDB001, and contribute to the effort to advance the field of #immunotherapy for cancer.

[Matthew W. DeAngelis @matthew2d]

(2/3) During my time at @7and8biopharma I had the opportunity to work alongside a small team of talented and dedicated professionals, and I very much enjoyed learning and growing together with you…!

[VJ Oncology @VJOncology]

We had a fantastic interview w/ @RobertAndtbacka (@7and8biopharma) on intratumoral therapy!

Stay tuned for more #SITC21 content on 👉https://t.co/ys1d8pDAKO👈

@sitcancer #ImmunoOnc #Oncology

[Matthew W. DeAngelis @matthew2d]

We're excited to share more promising interim data from our TLR7/8 dual agonist program... presented today at the @sitcancer 2021 Annual Meeting! @7and8biopharma

[7and8biopharma @7and8biopharma]

BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the @sitcancer Annual Meeting #SITC21 https://t.co/wDzrNgTZcZ

[7and8biopharma @7and8biopharma]

BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the @sitcancer Annual Meeting #SITC21 https://t.co/wDzrNgTZcZ

[Matthew W. DeAngelis @matthew2d]

@nimivashi15 @Ses_ma_ili Thank you for sharing this

[Matthew W. DeAngelis @matthew2d]

@biopharmasleuth Beautiful!

[Matthew W. DeAngelis @matthew2d]

@PatrickHwuMD @carlhjune @sitcancer The primer program was great! #SITC21

[Matthew W. DeAngelis @matthew2d]

@JennGuerriero @GabrilovichLab @sitcancer Great session today at @sitcancer #SITC21 … thank you!

[Matthew W. DeAngelis @matthew2d]

@maggiesmithpoet @acweyand Great advice!!!

[Matthew W. DeAngelis @matthew2d]

“Wink at small faults; for thou hast great ones.”
Thomas Fuller (II), 1731
#quotes #aphorisms